Ionis-AstraZeneca Heart Trial Fails; Analysts See Neutral-to-Negative Read-Through for Alnylam
Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.
Eplontersen failed to reduce heart events in 1,432 ATTR-CM patients. Results raise questions on silencer-plus-stabilizer use and for Alnylam’s pipeline.
Senior source tells Reuters there are no talks between AstraZeneca and Bristol Myers Squibb, ending $400B merger rumors and lifting shares.
Cancer drugs drive sales for both, with direct overlaps like Imfinzi and Opdivo raising antitrust risks.
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
The new treatment, given with fulvestrant with or without palbociclib, nearly quadrupled progression-free survival versus standard therapy.
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.